| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/25/2013 | EP2640702A1 3-(aminoaryl)-pyridine compounds |
| 09/25/2013 | EP2640698A1 Nampt and rock inhibitors |
| 09/25/2013 | EP2640697A1 4-substituted-3-phenylsulfanylmethyl-bicyclo[3.1.0]hexane compounds as mglur 2/3 antagonists |
| 09/25/2013 | EP2640690A1 Substituted amino bisphenyl pentanoic acid derivatives as nep inhibitors |
| 09/25/2013 | EP2640689A1 Substituted carbamoylcycloalkyl acetic acid derivatives as nep inhibitors |
| 09/25/2013 | EP2640687A1 4-SUBSTITUTED-3-BENZYLOXY-BICYCLO[3.1.0]HEXANE COMPOUNDS AS mGluR 2/3 ANTAGONISTS |
| 09/25/2013 | EP2640684A1 Methods for enhancing oxygenation of jeopardized tissue |
| 09/25/2013 | EP2640469A1 Signal transduction pathway modulation |
| 09/25/2013 | EP2640468A1 Method of administration and treatment |
| 09/25/2013 | EP2640467A1 Crystalline form of an inhibitor of mdm2/4 and p53 interaction |
| 09/25/2013 | EP2640433A1 Local vascular delivery of adenosine a2a receptor agonists to reduce myocardial injury |
| 09/25/2013 | EP2640427A1 Use of cyanine dyes for the detection of tau for diagnosis of early-stage tauopathies |
| 09/25/2013 | EP2640401A1 Compositions with antibacterial and wound healing activity |
| 09/25/2013 | EP2640400A1 Poly(amide) polymers for the delivery of oligonucleotides |
| 09/25/2013 | EP2640399A2 Methods and compositions for modulating pd1 |
| 09/25/2013 | EP2640398A1 Methods for treating chronic or unresolvable pain and/or increasing the pain threshold in a subject and pharmaceutical compositions for use therein |
| 09/25/2013 | EP2640397A1 Methods for the treatment of fibromyalgia and chronic fatigue syndrome |
| 09/25/2013 | EP2640396A1 Benzodiazepine derivatives, compositions and methods for treating cognitive impairment |
| 09/25/2013 | EP2640395A2 Treatment of addiction and impulse-control disorders using pde7 inhibitors |
| 09/25/2013 | EP2640394A2 Protection of renal tissues from ischemia through inhibition of the proliferative kinases cdk4 and cdk6 |
| 09/25/2013 | EP2640393A2 Cbp/catenin antagonists for enhancing asymmetric division of somatic stem cells |
| 09/25/2013 | EP2640392A2 Substituted 4-(selenophen-2(or 3)-ylamino)pyrimidine compounds and methods of use thereof |
| 09/25/2013 | EP2640391A1 Pyridazine derivatives, compositions and methods for treating cognitive impairment |
| 09/25/2013 | EP2640390A2 Methods of treating cancer |
| 09/25/2013 | EP2640389A1 Transdermal therapeutic system comprising buprenorphine |
| 09/25/2013 | EP2640388A1 Quinolinone derivatives |
| 09/25/2013 | EP2640387A1 Method of treatment with braf inhibitor |
| 09/25/2013 | EP2640386A1 Combination of checkpoint kinase 1 inhibitors and wee 1 kinase inhibitors |
| 09/25/2013 | EP2640385A1 Preselection of subjects for therapeutic treatment based on hypoxic status |
| 09/25/2013 | EP2640384A1 Preselection of subjects for therapeutic treatment with oxygen sensitive agents based on hypoxic status |
| 09/25/2013 | EP2640383A1 Method for treating breast cancer and ovarian cancer |
| 09/25/2013 | EP2640382A1 Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol |
| 09/25/2013 | EP2640381A2 Cannabinoid receptor antagonists-inverse agonists useful for treating metabolic disorders, including obesity and diabetes |
| 09/25/2013 | EP2640380A1 Pharmaceutical combination of paclitaxel and a cdk inhibitor |
| 09/25/2013 | EP2640379A2 Low dose cannabinoid medicaments |
| 09/25/2013 | EP2640378A1 Treatment of inflammation with certain alpha-7 nicotinic acid receptor agonists in combination with acetylcholinesterase inhibitors |
| 09/25/2013 | EP2640377A1 Fgfr1 extracellular domain combination therapies |
| 09/25/2013 | EP2640376A2 Caffeic acid derivatives and their use in improving neuronal cell viability |
| 09/25/2013 | EP2640375A1 Method of treating contrast-induced nephropathy |
| 09/25/2013 | EP2640374A1 Apomorphine by pulmonary inhalation, oprionally in combination with l-dopa or a dopamine agonist for use in the treatment of parkinson |
| 09/25/2013 | EP2640373A1 Treatment of type ii diabetes and diabetes-associated diseases with safe chemical mitochondrial uncouplers |
| 09/25/2013 | EP2640372A1 Preselection of subjects for therapeutic treatment with elesclomol based on hypoxic status |
| 09/25/2013 | EP2640371A1 Vasoprotective and cardioprotective antidiabetic therapy |
| 09/25/2013 | EP2640370A2 Compositions for transdermal delivery of active agents |
| 09/25/2013 | EP2640369A1 Methods of treating tumors |
| 09/25/2013 | EP2640368A1 Controlled release mucoadhesive systems |
| 09/25/2013 | EP2640367A2 Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture |
| 09/25/2013 | EP2640366A2 Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture |
| 09/25/2013 | EP2640365A1 Pharmaceutical composition comprising krebs cycle precursor salt, in particular citrate salt, and use thereof as a medicament |
| 09/25/2013 | EP2640364A1 Pharmaceutical composition comprising bicarbonate salt, and use thereof as a medicament in the treatment and/or prevention of urinary lithiasis and related diseases |
| 09/25/2013 | EP2640363A1 Pharmaceutical composition comprising citrate and bicarbonate salts, and use thereof for treating cystinuria |
| 09/25/2013 | EP2640362A1 Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate |
| 09/25/2013 | EP2640360A2 Therapeutic agent formulations for implanted devices |
| 09/25/2013 | EP2640358A1 Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same |
| 09/25/2013 | EP2640355A1 Stable oral pharmaceutical compositions of montelukast |
| 09/25/2013 | EP2640203A1 Excipient from trigonella foenum-graceum seeds and process for preparation thereof |
| 09/25/2013 | EP2640190A1 Modified nicotinic compounds and related methods |
| 09/25/2013 | EP2640189A1 3-deutero-pomalidomide |
| 09/25/2013 | EP2640188A1 Nanoparticle isoflavone compositions & methods of making and using the same |
| 09/25/2013 | CN103328983A Use of dronedarone for the preparation of a drug for use in the management of the risk of liver injury |
| 09/25/2013 | CN103328978A Use of stathmin as a biomarker of drug response to furazanobenzimidazoles |
| 09/25/2013 | CN103328633A Nucleic acid molecules inducing RNA interference, and uses thereof |
| 09/25/2013 | CN103328494A Novel derivatives of oxazaphosphorines that are pre-activated, use and method of preparation |
| 09/25/2013 | CN103328493A Novel phosphonic acids as s1p receptor modulators |
| 09/25/2013 | CN103328487A Imidazole derivatives as pde10a enzyme inhibitors |
| 09/25/2013 | CN103328486A Fused aminodihydrothiazine derivatives useful as BACE inhibitors |
| 09/25/2013 | CN103328485A Benzoxazepines as inhibitors of mTOR and methods of their use and manufacture |
| 09/25/2013 | CN103328482A New bicyclic compound for modulating G protein-coupled receptors |
| 09/25/2013 | CN103328480A Condensed imidazolylimidazoles as antiviral compounds |
| 09/25/2013 | CN103328479A 7-hydroxy-pyrazolo[1,5-A] pyrimidine compounds and their use as CCR2 receptor antagonists |
| 09/25/2013 | CN103328478A Piperidinone carboxamide azaindane cgrp receptor antagonists |
| 09/25/2013 | CN103328477A Pharmaceutical composition comprising pyridone derivatives |
| 09/25/2013 | CN103328476A Optically-active diazabicyclooctane derivative and method for manufacturing same |
| 09/25/2013 | CN103328474A Salts and crystalline forms of an apoptosis-inducing agent |
| 09/25/2013 | CN103328473A Substituted azaindazole compounds |
| 09/25/2013 | CN103328472A Imidazopyridines as respiratory syncytial virus antiviral agents |
| 09/25/2013 | CN103328469A Pyrrole derivative and process for production thereof |
| 09/25/2013 | CN103328468A Alpha-7 nicotinic receptor modulators for the treatment of pain, a psychotic disorder, cognitive impairment or alzheimer's disease |
| 09/25/2013 | CN103328467A Hydantoin derivatives useful as KV3 inhibitors |
| 09/25/2013 | CN103328466A Novel specific HCV NS3 protease inhibitors |
| 09/25/2013 | CN103328463A Chromene derivatives and their analoga as wnt pathway antagonists |
| 09/25/2013 | CN103328461A Compositions and methods of using crystalline forms of wortmannin analogs |
| 09/25/2013 | CN103328454A 1,4 oxazines as BACE1 and/or BACE2 inhibitors |
| 09/25/2013 | CN103328451A Compounds for the reduction of beta-amyloid production |
| 09/25/2013 | CN103328450A Crystalline pharmaceutically active ingredients |
| 09/25/2013 | CN103328449A Novel tetrahydroquinoline derivatives |
| 09/25/2013 | CN103328447A Compounds as c-Met kinase inhibitors |
| 09/25/2013 | CN103328446A Novel 4-amino-n-hydroxy-benzamides for the treatment of cancer |
| 09/25/2013 | CN103328442A Azetidine derivatives useful for the treatment of metabolic and inflammatory diseases |
| 09/25/2013 | CN103328441A Process for the manufacture of ajoene derivatives |
| 09/25/2013 | CN103328438A Aryloxyurea compound and pest control agent |
| 09/25/2013 | CN103328436A New aryl-benzocycloalkyl amide derivatives |
| 09/25/2013 | CN103328433A Analgesic compounds, methods, and formulations |
| 09/25/2013 | CN103328010A Use of cyanine dyes for the detection of tau for diagnosis of early-stage tauopathies |
| 09/25/2013 | CN103328006A Preparation comprising insulin, nicotinamide and an amino acid |
| 09/25/2013 | CN103327999A Composition for promoting lipolysis |
| 09/25/2013 | CN103327994A Combination therapy for prostate cancer using botanical compositions and bicalutamide |
| 09/25/2013 | CN103327993A Pharmaceutical composition comprising extract of lonicera japonica for prevention and treatment of gastroesophageal reflux disease |
| 09/25/2013 | CN103327985A Devices and methods for intravaginal delivery of drugs and other substances |
| 09/25/2013 | CN103327984A Injectable compositions for mastitis comprising an NSAID and an antibiotic in a non-aqueous solvent |